Table 3.
Predictors of overall survival in univariate and multivariate analyses in Cox regression analysis
| Characteristic | Univariate analysis
|
Multivariate analysis
|
||||||
|---|---|---|---|---|---|---|---|---|
| P (Cox) | HR | 95% CI
|
P (Cox) | HR | 95% CI
|
|||
| Lower | Upper | Lower | Upper | |||||
| Age, years ( <50 vs. ≥50) | 0.643 | 0.843 | 0.409 | 1.738 | – | – | – | – |
| Tumor size | 0.406 | 1.150 | 0.827 | 1.598 | – | – | – | – |
| Lymph node metastases (positive vs. negative) | 0.922 | 0.962 | 0.446 | 2.074 | – | – | – | – |
| HER2 status (positive vs. negative) | 0.148 | 1.333 | 0.903 | 1.968 | – | – | – | – |
| Hormone receptor status (positive vs. negative) | 0.891 | 1.053 | 0.504 | 2.200 | – | – | – | – |
| Number of CTCs at baseline (<5 vs. ≥5) | 0.033 | 2.175 | 1.063 | 4.453 | 0.043 | 2.443 | 1.028 | 5.809 |
| Number of CTCs at 1st follow up (<5 vs. ≥5) | 0.010 | 3.096 | 1.313 | 7.302 | – | – | – | – |
| HER2-positive CTCs at baseline | 0.677 | 1.226 | 0.470 | 3.193 | – | – | – | – |
| HER2-positive CTCs at 1st follow up | 0.019 | 3.210 | 1.212 | 8.502 | 0.180 | 2.023 | 0.722 | 5.669 |
| Number of therapies | 0.006 | 1.253 | 1.067 | 1.471 | 0.001 | 1.349 | 1.126 | 1.616 |
CI confidence interval, HR hazard ratio, CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2